Evidence map›Paper›PMID 32331365›Full record

ArticleJournal of clinical medicine2020

Iron Deficiency: Impact on Functional Capacity and Quality of Life in Heart Failure with Preserved Ejection Fraction.

Alex Alcaide-Aldeano, Alberto Garay, Lídia Alcoberro, Santiago Jiménez-Marrero, Sergi Yun, Marta Tajes, Elena García-Romero, Carles Díez-López, José González-Costello, Gemma Mateus-Porta and 4 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07053475 (IRONICA), which is not on this map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07053475 phase4terminatednot on this mapstarted 2025, after this paper: background citation

IRONICA: IRON Repletion in Congestive Heart Failure - A Randomized Controlled Trial Comparing Oral Versus IV Approaches

TypeinterventionalSponsorSyed Hamza MufarrihRan2025 to 2026Enrolled42ConditionsHeart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure With Preserved Ejection Fraction (HFPEF), Iron DeficiencyArmsFerric Carboxymaltose, Ferrous Sulfate
3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Benefits of intravenous iron supplementation in heart failure.Global cardiology science & practice · 2024
    Article
  9. Article
  10. Article
  11. Review
  12. Iron Deficiency in Heart Failure: A Korea-Oriented Review.International journal of heart failure · 2023
    Review
  13. Review
  14. Article
  15. Treatment of Iron Deficiency in Heart Failure.Current cardiology reports · 2023
    Review
  16. Observational
  17. Article
  18. Article
  19. Review
  20. Iron Deficiency and Deranged Myocardial Energetics in Heart Failure.International journal of environmental research and public health · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Alex Alcaide-AldeanoUniversity of Barcelona, School of Medicine, 08036 Barcelona, Spain.ORCID 0000-0002-0681-799X
Alberto GarayCommunity Heart Failure Unit, Department of Cardiology, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.
Lídia AlcoberroCommunity Heart Failure Unit, Department of Cardiology, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.
Santiago Jiménez-MarreroCommunity Heart Failure Unit, Department of Cardiology, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.ORCID 0000-0002-4574-4252
Sergi YunCommunity Heart Failure Unit, Department of Cardiology, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.ORCID 0000-0003-4858-9566
Marta TajesCommunity Heart Failure Unit, Department of Cardiology, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.
Elena García-RomeroBellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08907 Barcelona, Spain.ORCID 0000-0003-4090-6571
Carles Díez-LópezBellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08907 Barcelona, Spain.
José González-CostelloUniversity of Barcelona, School of Medicine, 08036 Barcelona, Spain.
Gemma Mateus-PortaDepartment of Cardiology, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.
Miguel Cainzos-AchiricaJohns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Cristina EnjuanesCommunity Heart Failure Unit, Department of Cardiology, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.
Josep Comín-ColetUniversity of Barcelona, School of Medicine, 08036 Barcelona, Spain.ORCID 0000-0001-8780-720X
Pedro MolinerCommunity Heart Failure Unit, Department of Cardiology, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.ORCID 0000-0002-5511-8597
Bellvitge University Hospital · ESJohns Hopkins University · USUniversitat de Barcelona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The effects of iron deficiency (ID) have been widely studied in heart failure (HF) with reduced ejection fraction. On the other hand, studies in HF with preserved ejection fraction (HFpEF) are few and have included small numbers of participants. The aim of this study was to assess the role that ID plays in functional capacity and quality of life (QoL) in HFpEF while comparing several iron-related biomarkers to be used as potential predictors. ID was defined as ferritin <100 ng/mL or transferrin saturation <20%. Submaximal exercise capacity, measured by the 6-min walking test (6MWT), and QoL, assessed by the Minnesotta Living with Heart Failure Questionnaire (MLHFQ), were compared between iron deficient patients and patients with normal iron status. A total of 447 HFpEF patients were included in the present cross-sectional study, and ID prevalence was 73%. Patients with ID performed worse in the 6MWT compared to patients with normal iron status (ID 271 ± 94 m vs. non-ID 310 ± 108 m,

Indexed as

6-min walking test6MWTheart failure with preserved ejection fractionHFpEFiron deficiencyMLHFQquality of lifesubmaximal exercise capacity

Identifiers

PMID32331365
PMCPMC7230551
OpenAlexW3019812724

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.